Generic Drugs and Biosimilars December 14-16, 2017 Rome, Italy

An overexploitation approach for cell culture based modular bioprocessing

Ravindra Patel OmniBRx Biotechnologies, India

In the battle of controlling healthcare costs, the high cost pharmaceuticals, especially biologics has become an important issue. Successful production planning requires consideration of cost factors such as manufacturing cost, capital investment to build new facilities or to retrofit existing ones, as well as the inventory costs. The cost attributed to the opportunity lost in selling the product or failure to meet market demand is also considered as the inventory cost. Any unplanned downtime could severely affect the customer service level, if facility utilization is too high. Underutilization of manufacturing facilities conversely suggests a misplaced investment in capacity. The overexploitation approach is designed to mitigate the above described facility constrains due to its power of combining the benefits of perfusion & fed batch processing mode with adequate elimination of facility constrains of fed-batch bioprocessing.

RavindraPatel@gmail.com